Aminoacyl-tRNA synthetases (ARSs) are essential, ubiquitously expressed enzymes that charge tRNA molecules with cognate amino acids in the cytoplasm and mitochondria. 1 Mutations in 32 ARS loci have been implicated in recessive disease, and the associated phenotypes tend to involve a wide array of tissues. [2] [3] [4] The genotypes of subjects with ARS-mediated recessive disorders suggest a loss-of-function mechanism for disease pathogenesis but are also consistent with the presumbed lethality of complete loss of ARS function. Specifically, subjects are compound heterozygous for one missense mutation and one null allele, compound heterozygous for two missense mutations, or homozygous for a single missense mutation. 2 Consistent with this notion, functional studies have revealed that recessive disease-associated ARS mutations cause reduced protein abundance in immunoblot assays, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] decreased mutant enzyme activity via in vitro kinetic assays, 9, [18] [19] [20] [21] [22] [23] [24] [25] and/or diminished ability of the mutated gene to support cellular growth in yeast complementation assays. 12, 13, 21, 22, [26] [27] [28] [29] [30] [31] [32] [33] As such, impaired protein translation as a consequence of decreased tRNA charging is the most likely molecular mechanism for ARS-mediated recessive disease. 2 Here, we report on four affected individuals from three unrelated families. These individuals have similar clinical presentations (Table S1 ) and bi-allelic loss-of-function variants in cysteinyl-tRNA synthetase (CARS [MIM: 123859] ). The appropriate, institute-specific review boards approved all studies, and informed consent was obtained from all subjects. The individual from family 1 (subject 1-3, Figure 1A ) is of mixed European and French-Canadian descent and was enrolled in the NIH Undiagnosed Diseases Program. He was born at 33 weeks gestation to asymptomatic parents and presented with intrauterine growth retardation and microcephaly. In childhood he presented with failure to thrive, non-progressive cognitive delay, peripheral neuropathy, osteoporosis, proportionate short stature, recurrent hernias, mild aortic root dilatation, recurrent elbow dislocation, feeding difficulties, esophagitis requiring Nissen fundoplication, urinary retention, and chronic pain. At age 24 he was diagnosed with hypothalamic hypogonadism and delayed puberty, as well as type II diabetes mellitus. On examination he had dysmorphic features; a barrel-shaped trunk with wasting of the distal extremities; hypospadias with chordee; hyperextensible joints; myopia; central hypotonia but increased extremity tone; prominent lateral ventricles and sulci with mild cerebral atrophy upon brain MRI ( Figures 2A-C) ; and fine, brittle hair ( Figure 3A ) and brittle nails ( Figure S1A and S1B). Polarized light microscopy of hair shafts revealed moderate tiger-tail patterns compared to those of controls ( Figures  4A and 4B ). Subject 1-3 is currently 34 years old and has mild motor, language, and cognitive disabilities.
The individual from family 2 (subject 2-4, Figure 1B ) is of Dutch descent, has asymptomatic parents, and was born at 38 weeks' gestation via elective cesarean section prompted by intrauterine growth retardation. As a result of a small atrial septal defect and failure to thrive, she was hospitalized for two months after birth. In childhood she developed restless behavior, poor sleep, mild dystonia, ataxic hand movements, poor coordination, and developmental delay. At age 30 she was diagnosed with diabetes mellitus. A CT scan of the head when she was 2 years old was normal. A brain MRI performed when she was 20 years old revealed areas of apparent delayed myelination; decreased white-matter volume; prominence of cerebellar folia; a small corpus striatum; hypoplasia of the corpus callosum; and mild, globally diffuse cerebral and cerebellar atrophy ( Figures 2D-2F ). The quality of the MRI and the lack of a repeat MRI did not allow distinction between hypomyelination and demyelination. On examination she had microcephaly; fine facial features; fragile nails; and sparse, brittle, and thin hair ( Figure 3B ). Light microscopy of hair shafts revealed trichoschisis and trichorrhexis nodosa, polarized microscopy showed weak but consistent tiger tail banding ( Figure 4C ), and scanning electron microscopy showed longitudinal grooves (data not shown). Subject 2-4 is currently 35 years old and has a moderate level of motor, language, and cognitive disability.
Family 3 includes two affected siblings (subjects 3-3 and 3-4, Figure 1C ) who are of Dutch descent and were born to asymptomatic parents. Both subjects presented with developmental delay, mild spastic ataxia, a wide-based gait, pyramidal signs, liver steatosis, and thin hair ( Figures  3C and 3D ). Polarized microscopy of hair shafts revealed trichorrhexis and moderate tiger-tail patterns in subject 3-3 ( Figure 4D ) and mild tiger-tail patterns in subject 3-4 (data not shown). Subject 3-3 was observed from infancy because of unexplained failure to thrive, cholestasis, and fat malabsorption and had complex partial and generalized seizures. Subject 3-4 presented at two months with congenital nystagmus and high myopia; at nine months she had repeated convulsions associated with fever and was diagnosed with hepatomegaly and steatosis. Brain CT of subject 3-3 revealed hemiatrophy and a wide right ventricle (data not shown). Subject 3-3 is currently 25 years old and has a moderate level of motor, language, and cognitive disability. Subject 3-4 is currently 20 years old and has a mild level of motor, language, and cognitive disability. Tiger-tail structural anomalies are typical of individuals affected by trichothiodystrophy (TTD); 34 indeed, this was the initial clinical diagnosis of subject 2-4. Because TTD is often caused by DNA-repair defects, thorough analysis of DNA-repair capacity was performed on skin fibroblasts from subjects 1-3, 2-4, and 3-3. This analysis did not reveal any defects ( Figure S2 ). To identify candidate variants for the unexplained phenotypes observed in our subjects, we performed exome sequencing (ES) on all affected individuals and their unaffected parents ( Figure 1A-1C) . In Family 1, ES was performed using the Illumina HiSeq2000 platform and the TrueSeq capture kit as previously described. [35] [36] [37] [38] Sequence data were aligned to the human reference genome (hg19), and variants were filtered with VarSifter 39 on the basis of allele frequencies in the NIH-UDP cohort. 36, 40, 41 In families 2 and 3, trio ES was performed after DNA enrichment with Agilent Sureselect Exome V4 Capture and subsequently run on the HiSeq platform (101bp paired-end, Illumina) with an average depth coverage of 503-1003; sequences were mapped with BWA. Variants were detected with the Genome Analysis Toolkit, and the VCF files were filtered with Cartagenia software (version 3.0.7). A summary of the ES analysis is provided in Table S2 . Analysis of ES data revealed that all four affected individuals are homozygous or compound heterozygous for CARS variants (Table 1 and Figure 1 ). Variant analysis by ES in family 1 revealed additional candidate diseasecausing variants in DEAF1 (MIM: 602635), SOX30 (MIM: 606698), and PTPN13 (MIM: 600267). In family 2, ES analysis revealed no additional candidate variants. In family 3, ES analysis revealed candidate variants in ZNF185 (MIM: 300381). Importantly, the phenotypic similarity among subjects is consistent with the finding that all three families carry CARS variants, which were the only common candidates identified via ES; it should be noted that the research groups studying these families were connected via GeneMatcher 42 on the basis of the detection of
Sanger sequencing analysis of genomic DNA isolated from subjects' fibroblasts confirmed each variant ( Figures  1 and 5A ). Subject 1-3 is homozygous for c.2061dup, which predicts a frameshift variant, p.Ser688Glnfs*2 (Table 1). This variant is present in the gnomAD database 43 Figure 2. Subjects with CARS Variants Present with Central Nervous System Features Sagittal T1-weighted (A) and axial T2-weighted (B and C) imaging of subject 1-3 shows moderate cerebral atrophy, a thin corpus callosum (A; arrow), mild atrophy of the superior cerebellar vermis (A; arrowhead), thin cerebellar folia, incomplete falx cerebri, incomplete tentorium, and variant anatomy of the circle of Willis. Sagittal T1-weighted imaging on subject 2-4 shows thin splenium of corpus callosum (D; arrow) and mild atrophy of the vermis (D; arrowhead). T2-weighted axial images of subject 2-4 show moderate global cerebral atrophy, deep sulci (E), thin cerebellar folia (F), and decreased white-matter volume, but globally normal myelination (D-F). only in the heterozygous state (2/251,406). Subject 2-4 is compound heterozygous for two CARS variants. The maternally inherited variant (c.1022G>A; p.Arg341His) is present in gnomAD (8/178,368); however, no homozygous individuals were detected in this database ( Table 1) . The paternally inherited variant (c.1138C>T; p.Gln380*) is present in gnomAD with a very low frequency (1/184,276) ( Table 1) . Subjects 3-3 and 3-4 are both compound heterozygous for two CARS missense variants. The maternally inherited variant (c.1076C>T; p.Ser359Leu) is present in the gnomAD database (8/194,406) ; however, no homozygous individuals were detected ( Table 1 ). The paternally inherited variant (c.1199T>A; p.Leu400Gln) is not present in the gnomAD database (Table 1) .
CARS is the sole enzyme responsible for charging tRNA Cys molecules in the cytoplasm of mammalian cells;
CARS2 is a nuclear-encoded enzyme responsible for charging tRNA Cys molecules in mitochondria. 1 There are two protein isoforms of CARS; they differ in their C-terminal sequences and result from alternative splicing of the penultimate exon. 44 CARS is a class I ARS enzyme containing a catalytic domain that activates and transfers cysteine to tRNA. CARS also contains an anticodon binding domain for tRNA recognition. [45] [46] [47] The p.Arg341His, p.Ser359Leu, p.Gln380*, and p.Leu400Gln variants all affect residues that map to the catalytic domain ( Figure 5B ). The p.Gln380* variant is predicted to result in a truncated protein missing 368 of the 748 CARS amino acid residues; such a truncation would result in the complete loss of the anticodon-binding domain. The p.Ser688Glnfs*2 variant maps to the C terminus in a region that is conserved among eukaryotes and that is important for the binding specificity between CARS and tRNA Cys . 48 We assessed the evolutionary conservation of each affected CARS amino acid residue by aligning protein sequences of CARS orthologs from multiple species. The Arg341 residue is conserved among all analyzed species; the Leu400 residue is conserved in all analyzed species except bacteria; and the Ser359 residue is conserved among the human, mouse, and zebrafish CARS proteins ( Figure 5C ). The p.Ser688Glnfs*2 variant is predicted to truncate CARS by 60 amino acids. Of those 60 amino acids, 28% (17/60) are conserved among all analyzed species except bacteria, and 70% (42/60) are conserved among the human, mouse, and zebrafish CARS proteins ( Figure 5C and data not shown). The p.Gln380* and p.Ser688Glnfs*2 CARS variants encode premature stop codons and are therefore predicted to reduce the expression of full-length CARS. To test this prediction, we performed immunoblot analyses on protein isolated from fibroblasts from both affected individuals and unaffected controls; for these analyses, we used antibodies against CARS (sc-390230, Santa Cruz, purified mouse antibody, 1:250 dilution) and actin (A5060, Sigma, purified rabbit antibody, 1:5000 dilution). The molecular weights of the two wild-type CARS isoforms are predicted to be 82 kDa and 85 kDa; 44 these isoforms appear as a single band when lysates are electrophoresed on a 4%-20% tris-glycine gel ( Figure 6A ). In protein isolated from subject 1-3's fibroblasts, there was a single band at 78 kDa, consistent with the predicted size of the truncated protein ( Figure 6A ). We therefore conclude that a truncated protein is expressed and stable, which is consistent with the viability of subject 1-3. In protein isolated from subject 2-4's fibroblasts, the amount of full-length CARS protein were significantly reduced in comparison to the amount in control cells ( Figure 6A ). This could be explained by the ablation of the expression of full-length CARS by the p.Gln380* variant; no truncated protein was detectable upon repeated analysis of an entire blot ( Figure S3 ). In protein isolated from subject 3-3's fibroblasts, the amount of full-length CARS protein was similar to that of control cells ( Figure 6A ), which is consistent with the expression of two expressed and stable missense CARS protein variants in this subject. To determine whether the identified CARS variants affect subcellular protein localization, we performed immunofluorescence analysis by using a CARS antibody (H00000833-B01P, Novus Biologicals). These studies did not reveal any gross changes in CARS protein localization ( Figure S4 ). To assess the effect of CARS variants in the context of the affected individuals' genotypes, we performed steady-state aminoacylation reactions on protein lysates from fibroblasts taken from those individuals. GARS activity was simultaneously measured as an internal control. In brief, assays were performed at 37 C in reaction buffer Labeled amino acids were quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Intra-assay variation was <15%, and no decreases were observed for GARS (internal control) activity in affected versus unaffected individuals (p value ¼ 0.624). Statistical significance was determined with a one-tailed, unpaired t test. Compared to control cells and those isolated from the unaffected mother in family 1, each subject showed significantly reduced CARS activity ( Figure 6B ; p value < 0.001): 70% reduction for subject 1-3, 80% reduction for subject 2-4, and 40% reduction for subject 3-3. Importantly, these data are consistent with a loss-of-function effect for each CARS variant.
To evaluate the functional consequences of each CARS allele in isolation, we developed a yeast complementation assay. In brief, a haploid yeast strain was generated with the endogenous yeast CARS ortholog (YNL247W) deleted, and viability was maintained with YNL247W on a URA3-bearing maintenance vector. Each CARS variant was modeled in human CARS, which was reported to rescue loss of YNL247W. 49 Wild-type or mutant CARS (or wildtype YNL247W) was transformed into yeast, and growth was evaluated on 5-FOA medium, which selects for the spontaneous loss of the maintenance vector. 50 The amount of CARS protein present in transformed yeast was assessed via immunoblot analysis ( Figure S5 ). Wildtype YNL247W and wild-type human CARS rescued yeast viability, whereas an empty vector did not ( Figure 7A ). This is consistent with the finding that human CARS supports loss of the endogenous YNL247W and with YNL247W being an essential gene, respectively. The p.Gln380*, p.Leu400Gln, and p.Ser688Glnfs*2 variants did not support any yeast cell growth ( Figure 7A ), consistent with a loss-of-function effect. The p.Arg341His and p.Ser359Leu variants were associated with severely reduced but not ablated yeast cell growth ( Figure 7A ), consistent with hypomorphic alleles. To gain a more sensitive assessment of the hypomorphic p.Arg341His or p.Ser359Leu variants, we performed aminoacylation assays, which evaluate the kinetic properties of ARS variants and have been established as informative for studying disease-associated ARS alleles. 51 We tested recombinant human CARS proteins (wild-type, p.Arg341His, and p.Ser359Leu) for the ability to charge human cytoplasmic tRNA Cys with 35 S-labeled cysteine as previously described. 44, 52 Analysis of the initial rate of aminoacylation as a function of the tRNA substrate concentration showed that both mutant CARS proteins cause a reduction in enzyme activity ( Figure 7B and Table S3 ): p.Arg341His resulted in a 50% reduction in activity compared to that of wild-type CARS, and p.Ser359Leu resulted in a 84% reduction in activity compared to that of wild-type CARS. These data are consistent with the yeast complementation assay and the skin fibroblast results and indicate that each of these variants is a hypomorphic allele. In summary, we present clinical, genetic, and functional data that implicate CARS variants in a multi-system, recessive disease that includes microcephaly, developmental delay, and brittle hair and nails. The genetic and clinical evidence we present supports the pathogenicity of the identified CARS variants in several ways. First, three independent pedigrees displayed an overlapping phenotype with unique features, including brittle hair and nails; these data are consistent with a common underlying genetic etiology among the three families. Second, CARS variants segregate with the presumed recessive phenotype in all three families, and each affected subject is homozygous or compound heterozygous for variants that result in truncated proteins or that affect highly conserved amino acids. Third, our functional studies also strongly support the pathogenicity of each CARS variant. Specifically, each variant causes a loss-of-function effect in protein abundance, tRNA charging, or yeast complementation assays. Indeed, these assays are commonly used for demonstrating a loss-of-function effect for disease-associated ARS mutations. Aminoacylation assays have tested the effects of variants in 15 ARS genes implicated in recessive disease, and yeast complementation assays have tested the effects of variants in eight ARS genes implicated in recessive disease. 51 Using cell lysates from affected individuals to test aminoacylation activity is a technique that determines the effects of ARS mutations in the context of the affected individual's genome; these studies will be critical for future efforts to better classify the effect of disease-associated ARS genotypes on tRNA charging. Our functional studies on the disease-associated CARS variants also provide insight into the pathogenic mechanism of the clinical phenotype observed in our subjects. That is, the loss-of-function effects suggest that impaired tRNA charging leads to reduced, interrupted, or otherwise altered protein translation in the affected organ systems. This notion is consistent with previous reports of loss-offunction effects of variants in other ARS genes identified in individuals with recessive phenotypes. 2 An alternative-albeit less likely-possibility is that CARS has some non-canonical function that is unrelated to tRNA charging and that is affected by the variants described here, and that this function is particularly important for the affected tissues. Although CARS has been reported to function in cysteine polysulfidation 53 and ferroptosis, 54 further work is needed to identify secondary CARS functions that might be relevant to the phenotypes in our subjects. Importantly, phenotypic overlap between our subjects and others with ARS-mediated recessive disease further supports the pathogenicity of the identified CARS variants and indicates a common mechanism for ARS-related recessive disease. 2, 3, 7, 9, 56, 57 In addition to the above phenotypes, subject 1-3 has an axonal peripheral neuropathy, which has previously been associated with variants in five other ARS loci. 2 Severe depletion of tRNA charging might be responsible for the peripheral neuropathy in this (C) Hair cysteine index (percent of total protein lysate) in controls and TTDaffected individuals compared to individuals with bi-allelic CARS variants. Note that only subject 2-4 (two independent samples) falls within the range of TTD subjects. Only one sample each was assessed for subject 1-3, subject 3-3, and subject 3-4. individual; reduced enzyme function is a common feature of neuropathy-associated ARS variants. 2, 51 Interestingly, all four affected individuals described here have some degree of fine, brittle hair with microscopic shaft abnormalities; this characteristic has not been previously associated with disease-causing ARS variants. Hair and nails could be particularly susceptible to impairments in CARS function because of the high cysteine content of keratins expressed in these tissues. To begin to address this possibility, we performed quantitative analysis of hair amino acid composition after hydrolysis and followed this with liquid chromatography. Consistent with our hypothesis, this assay showed a lower cysteine to total amino acid index in hair from subject 2-4, which is within the range for individuals with TTD ( Figure 7C) . No other individual in our study showed such an effect on the hair cysteine index, but it is interesting to note that subject 2-4 had both the most abnormal hair structure and the most dramatic reduction in CARS activity ( Figure 6B ). At the moment, it is not clear why CARS deficiency renders individuals susceptible to other characteristic phenotypes such as liver steatosis and impairment of the central nervous system. Confirming our observations and determining whether the translation of cysteine-rich proteins is affected by impaired CARS activity will require further studies in appropriate animal models.
In conclusion, we present clinical, genetic, and functional data that implicate CARS variants in a multi-system, recessive disease that includes microcephaly, developmental delay, and brittle hair and nails. These findings expand the locus and clinical heterogeneity of ARS-related disease and further support the hypothesis that impaired tRNA charging followed by protein translation defects is the primary pathogenic mechanism of ARS-related recessive disease.
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